tiprankstipranks
Trending News
More News >

ADMA Biologics Announces $500M Share Repurchase Program

Story Highlights
ADMA Biologics Announces $500M Share Repurchase Program

Confident Investing Starts Here:

The latest update is out from ADMA Biologics ( (ADMA) ).

In the first quarter of 2025, ADMA Biologics reported a significant financial performance with a 40% increase in total revenue and an 81% rise in adjusted EBITDA year-over-year. The company announced a $500 million share repurchase program and a debt reorganization that reduced its cost of debt by 1.1%. Additionally, the FDA approved ADMA’s yield enhancement production process, expected to boost production output by 20%, supporting revenue growth and margin expansion. The company has increased its revenue guidance for 2025 and 2026, projecting total annual revenues to exceed $1.1 billion by 2030.

Spark’s Take on ADMA Stock

According to Spark, TipRanks’ AI Analyst, ADMA is a Outperform.

ADMA Biologics showcases strong financial performance with significant revenue and profit growth, improved operational efficiency, and robust cash flow generation, positioning it well for future growth. Technical indicators support a bullish outlook, though caution is advised due to overbought signals. Valuation is on the higher side with a P/E ratio suggesting potential overvaluation. The recent earnings call further highlights strong growth prospects, though pending regulatory approvals and audit delays present risks.

To see Spark’s full report on ADMA stock, click here.

More about ADMA Biologics

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics, particularly immunoglobulin therapies. The company operates within the immunocompromised patient population and maintains a fully controlled, end-to-end supply chain in the United States.

Average Trading Volume: 3,302,840

Technical Sentiment Signal: Buy

Current Market Cap: $5.52B

For an in-depth examination of ADMA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App